Metformin and cancer immunity

• 来源期刊: 中国药理学报（英文版）
• 年，卷（期）: 2020,（11）
• 所属期刊栏目: Review Article
• 页码范围: 1403-1409
• 页数: 7页
• 语种: 英文

摘要

The immune system plays an essential and central role in tumor cell differentiation,proliferation,angiogenesis,apoptosis,invasion,and metastasis.Over the past decade,cancer therapy has rapidly evolved from traditional approaches,such as surgery,chemotherapy,and radiotherapy,to revolutionary new treatment options with immunotherapy.This new era of cancer treatment options has now been clinically tested and applied to many forms of human malignancies,often with quite dramatic results.As we develop more effective combinations of cancer treatment,several agents have been recently investigated,putatively identified as anticancer agents,or immunostimulatory molecules.One such agent is metformin,originally developed as a fairly standard first-line therapy for patients with type-2 diabetes mellitus (T2DM).Given the underlying mechanisms of action,researchers began to examine the alternative functions and possible utility of metformin,finding that the cancer risk in patients with T2DM was reduced.It appears that metformin,at least in part,has an antitumor effect through activation of the 5'adenosine monophosphate-activated protein kinase (AMPK) signaling pathway.Moreover,numerous studies have demonstrated that metformin interferes with key immunopathological mechanisms that are involved in the pathological processes or associated with malignant progression.Such insights may shed light on further analyzing whether metformin enhances the effectiveness of the immunotherapy and overcomes the immunotherapy resistance in the patients.Herein,we provide a comprehensive review of the literature examining the impact of metformin upon the host immune system and cancer immunity.